Under construction – not a live service
Sign in
Taking people in BrazilPhase 2

Tests RO7837195 against placebo in moderate to severe ulcerative colitis

Tests RO7837195 against placebo in adults with active ulcerative colitis.

Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Key facts

Where
Aracaju, Belo Horizonte, Brasília, Curitiba, Fortaleza, Ja, Porto Alegre, Rio de Janeiro, Santo André, São Jose Do Rio Preto, São Paulo, and So Paulo, BrazilSee the 16 sites
Phase
Phase 2

Where in Brazil

  • Newdata Clinical TrialsAracaju, BrazilTaking people
  • Hospital Felicio RochoBelo Horizonte, BrazilTaking people
  • Chronos Pesquisa ClínicaBrasília, BrazilTaking people
  • L2IP - Instituto de Pesquisas Clínicas LtdaBrasília, BrazilTaking people
  • Associao Paranaense de Cultura APCCuritiba, BrazilTaking people
  • Centro Digestivo de CuritibaCuritiba, BrazilTaking people
  • HUWC - UFC - Hospital Universitrio Walter Cantdio - Universidade Federal do CearFortaleza, BrazilTaking people
  • CECIP - Centro de Estudos Clínicos do Interior PaulistaJa, BrazilTaking people
  • Hospital de Clnicas de Porto AlegrePorto Alegre, BrazilTaking people
  • Hospital Ernesto DornellesPorto Alegre, BrazilTaking people
  • Hospital Gloria DOr - Hospitais Integrados da Gavea S/ARio de Janeiro, BrazilTaking people
  • Pesquisare SaudeSanto André, BrazilTaking people
  • Kaiser ClinicaSão Jose Do Rio Preto, BrazilTaking people
  • BR Trials - Ensaios Clnicos e ConsultoriaSão Paulo, BrazilTaking people
  • Instituto de Assistencia Medica ao Servidor Publico Estudo EstadualSão Paulo, BrazilTaking people
  • CPQuali Pesquisa Clinica LtdaSo Paulo, BrazilTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Genentech, Inc.
Trial code
NCT06979336EU 2025-520690-39-00
Record updated
27 October 2026
Original description
The purpose of this study is to evaluate the efficacy of RO7837195 compared with placebo in participants with moderately to severely active ulcerative colitis for whom prior treatment with conventional and/or advanced therapies has failed.Read full original descriptionShow less

A Phase IIb, Multicenter, Double-blind, Placebo-controlled Induction Study With an Active Treatment Extension to Assess the Efficacy, Safety, and Pharmacokinetics of RO7837195 in Patients With Moderately to Severely Active Ulcerative Colitis

The purpose of this study is to evaluate the efficacy of RO7837195 compared with placebo in participants with moderately to severely active ulcerative colitis for whom prior treatment with conventional and/or advanced therapies has failed.

Inclusion: Diagnosis of ulcerative colitis (UC) established at least 3 months; Moderately to severely active UC assessed by mMS; Inadequate response, loss of response, or intolerance to conventional or advanced therapies for UC.

Exclusion: Prior extensive colonic resection, subtotal or total colectomy, or planned surgery for UC; Treatment with an advanced therapy targeted at tumor necrosis factor-like cytokine 1A (TL1a); Inadequate response, loss of response, or intolerance to treatment of UC with an advanced therapy targeted at IL-12 and/or IL-23; Diagnosis of Crohn's disease or indeterminate colitis.

ClinicalTrials.gov NCT06979336 · EU CTIS 2025-520690-39-00

Under construction, not live – A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC) (NCT06979336) – Frontlight Research